Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) shares fell 3% during mid-day trading on Tuesday . The stock traded as low as $22.44 and last traded at $22.42. 312,175 shares changed hands during mid-day trading, a decline of 65% from the average session volume of 903,849 shares. The stock had previously closed at $23.10.
Wall Street Analysts Forecast Growth
GPCR has been the subject of several recent research reports. William Blair began coverage on shares of Structure Therapeutics in a research note on Friday, February 28th. They set an "outperform" rating for the company. Stifel Nicolaus assumed coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They set a "buy" rating and a $50.00 price objective for the company. Finally, HC Wainwright restated a "buy" rating and issued a $80.00 target price on shares of Structure Therapeutics in a report on Tuesday, April 22nd. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Structure Therapeutics currently has an average rating of "Buy" and a consensus price target of $81.29.
Read Our Latest Research Report on GPCR
Structure Therapeutics Stock Up 0.4 %
The company has a 50-day moving average price of $20.17 and a 200 day moving average price of $27.78. The firm has a market cap of $1.36 billion, a price-to-earnings ratio of -32.08 and a beta of -1.35.
Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.01. Equities analysts forecast that Structure Therapeutics Inc. will post -0.82 EPS for the current year.
Institutional Trading of Structure Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of GPCR. Janus Henderson Group PLC increased its position in Structure Therapeutics by 5.1% in the 4th quarter. Janus Henderson Group PLC now owns 4,159,888 shares of the company's stock worth $112,816,000 after purchasing an additional 203,010 shares during the last quarter. Deep Track Capital LP lifted its holdings in shares of Structure Therapeutics by 129.4% during the 4th quarter. Deep Track Capital LP now owns 2,800,000 shares of the company's stock valued at $75,936,000 after buying an additional 1,579,492 shares during the last quarter. Vestal Point Capital LP grew its stake in shares of Structure Therapeutics by 50.0% in the 4th quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company's stock valued at $46,782,000 after buying an additional 575,000 shares in the last quarter. Capital International Investors increased its holdings in Structure Therapeutics by 6.8% in the fourth quarter. Capital International Investors now owns 1,619,081 shares of the company's stock worth $43,909,000 after buying an additional 103,059 shares during the last quarter. Finally, Ameriprise Financial Inc. raised its position in Structure Therapeutics by 29.4% during the fourth quarter. Ameriprise Financial Inc. now owns 1,420,052 shares of the company's stock valued at $38,512,000 after acquiring an additional 322,601 shares in the last quarter. 91.78% of the stock is currently owned by hedge funds and other institutional investors.
About Structure Therapeutics
(
Get Free Report)
Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
Recommended Stories
Before you consider Structure Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.
While Structure Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
